IP Library Granted Patent US 11,413,240
Granted Patent B2
US 11,413,240 · App. 16/473,214 · Granted Aug 16, 2022

Methylene blue solution for the treatment of oral lesions

Inventor: Carlos Julio Roldan (Houston, TX)
Assignee: Board of Regents, The University of Texas System
A61K9/006A61K9/08A61K31/5415A61K45/06A61K47/02A61P1/00A61P17/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,413,240
App. No.
16/473,214
Granted
Aug 16, 2022
Kind
B2
Abstract

The present disclosure provides methods and compositions for the treatment of oral lesions in a subject comprising a methylene blue oral rinse.

Claims (20)

1. A method for treating cancer therapy-induced oral mucositis in a subject comprising selecting a subject having cancer and undergoing cancer therapy and administering to the oral mucosa of the subject a methylene blue oral rinse that is essentially free of chlorohexidine, in an amount effective to treat the oral mucositis, wherein the oral mucositis is not caused by herpes virus infection, herpangina, burns, tooth extraction, gingivitis, graft versus host disease or a microbial infection and the treatment is not to prevent oral mucositis.

2. The method of claim 1 , wherein the subject is suffering from pain or oral lesions.

3. The method of claim 1 , wherein the subject is in need of improving oral function-including improving the subject's ability to eat, swallow, and/or talk.

4. The method of claim 1 , wherein the methylene blue oral rinse comprises 0.01% to 1% methylene blue.

5. The method of claim 1 , wherein the methylene blue oral rinse comprises 0.05% to 0.2% methylene blue.

6. The method of claim 1 , wherein the methylene blue oral rinse comprises 0.025% to 0.05% methylene blue.

7. The method of claim 1 , wherein the methylene blue oral rinse comprises a saline solution.

8. The method of claim 1 , wherein administering comprises performing an oral swish and spit technique.

9. The method of claim 8 , wherein the oral swish and spit technique comprises taking 6 to 10 mL of the oral rinse in the mouth and holding the oral rinse at painful sites for at least 5 minutes before swishing and spitting.

10. The method of claim 2 , wherein pain is measured using a numeric rating scale and/or oral functioning scale.

11. The method of claim 10 , wherein the pain and/or lesions are decreased by at least 50% as compared to pain and/or lesions prior to administering the methylene blue oral rinse.

12. The method of claim 10 , wherein the pain and/or lesions are essentially completely relieved.

13. The method of claim 1 , wherein the subject has received or is undergoing chemotherapy, hematopoietic stem cell transplantation, bone marrow transplantation, and/or radiotherapy.

14. The method of claim 1 , wherein the subject has head and neck cancer, thyroid cancer, oral cancer, salivary gland cancer, acute myelocytic leukemia, acute lymphocytic leukemia, B cell lymphoma, chronic lymphocyte leukemia, or multiple myeloma.

15. The method of claim 1 , wherein administering is every 48 hours, every 24 hours, every 12 hours, or every 6 hours.

16. The method of claim 1 , wherein the oral rinse further comprises an analgesic.

17. The method of claim 1 , wherein the cancer therapy-induced oral mucositis is chemotherapy-induced oral mucositis.

18. The method of claim 1 , wherein the cancer therapy-induced oral mucositis is radiation-induced oral mucositis.

19. The method of claim 1 , wherein treating comprises relieving pain.

20. The method of claim 1 , wherein the oral rinse is essentially free of zinc sulfate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2020
From: ROLDAN, CARLOS JULIO
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 051865/0006 →
Continuity (3)
Provisional Application 62511773 · May 26, 2017
Provisional Application 62440221 · Dec 29, 2016
Related Publication 20200093733A1 · Mar 26, 2020